When a patient with Alzheimer dementia becomes agitated, check the physical environment for a trigger before pulling the trigger on a medication, dementia expert George Grossberg, MD, recommends.
According to George Grossberg, MD, a geriatric psychiatrist recognized for his research on treatment for neurocognitive disorders, reaching for medication first when a person with Alzheimer disease becomes agitated is a simple solution to a problem but certainly not always an appropriate or necessary one. In a recent interview with Patient Care,® Grossberg offered an example of using the patient's environment, or a change in that environment, as a first-line intervention to calm the behavior by reducing or eliminating a trigger. He explains in the short video above.
This transcript has been lightly edited for length and clarity.
Patient Care: Are there non-pharmacologic interventions that can be effective, or do they tend to be more effective in combination with medication?
George Grossberg, MD: So, I think there are a couple of important points about non-pharmacologic approaches, especially related to environmental triggers, which we should keep in mind.
Let me give you an example. I had a new patient whose family decided to move her to a skilled nursing facility. She’d been fairly calm and wasn’t causing any issues, but they placed her in a shared room with another patient who happened to be quite noisy. Soon enough, I received a call from the nursing staff saying my patient had become even noisier than her roommate. Naturally, they wanted a quick solution—medication, something immediate.
But I told them, 'Let’s pause for a moment and think this through. Is there a quieter room available or a roommate who might be less disruptive?' They found a quieter roommate for her, made the switch, and I didn’t get any more calls.
That’s a perfect example of a non-pharmacologic intervention that worked effectively because it addressed the environmental trigger specific to her situation.
George T Grossberg, MD, is the Samuel W. Fordyce professor and director of geriatric psychiatry in the department of psychiatry at Saint Louis University School of Medicine. He is a past president of the American Association for Geriatric Psychiatry and of the International Psychogeriatric Association. Grossberg's research focus includes behavioral symptoms in Alzheimer disease and novel therapies for neurocognitive disorders.
The CMS CED Policy Limits Treatment for Early Alzheimer's Disease: What It Is and How It Works
December 16th 2024The coverage with evidence development (CED) policy requires enrollment in an active clinical trial for an adult to be eligible for Medicare coverage of treatment for Alzheimer's disease.